An FPP synthase inhibitor
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Neridronic Acid

Item No. 29692

Technical Information
Formal Name
P,P′-(6-amino-1-hydroxyhexylidene)bis-phosphonic acid
CAS Number
79778-41-9
Synonyms
  • Neridronate
Molecular Formula
C6H17NO7P2
Formula Weight
Purity
≥95%
A crystalline solid
SMILES
NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O
InChi Code
InChI=1S/C6H17NO7P2/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14/h8H,1-5,7H2,(H2,9,10,11)(H2,12,13,14)
InChi Key
PUUSSSIBPPTKTP-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Neridronic acid is an amino bisphosphonate that inhibits farnesyl pyrophosphate (FPP) synthase (IC50 = 388.2 nM in a cell-free assay).1 It decreases the differentiation of RAW 264.7 cells into osteoclasts in a CRL-12257 co-culture model of osteoclastogenesis when used at concentrations ranging from 0.001 to 100 µM.2 Neridronic acid (30 µM) inhibits FGF2-induced proliferation and tube formation in human umbilical vein endothelial cells (HUVECs).3 It reduces the loss of trabeculae and increases bone density in the tibial metaphysis of growing rats when administered subcutaneously at a dose of 0.1 mg/kg per day.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Dunford, J.E., Kwaasi, A.A., Rogers, M.J., et al. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: Time-dependent inhibition of human farnesyl pyrophosphate synthase. J. Med. Chem. 51(7), 2187-2195 (2008).

    2. Nicolin, V., Bareggi, R., Baldini, G., et al. Effects of neridronic acid on osteoclasts derived by physiological dual-cell cultures. Acta Histochem. 109(5), 397-402 (2007).

    3. Ribatti, D., Nico, B., Mangieri, D., et al. Neridronate inhibits angiogenesis in vitro and in vivo. Clin. Rheumatol. 26(7), 1094-1098 (2007).

    4. Schenk, R., Eggli, P., Fleisch, H., et al. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif. Tissue Int. 38(6), 342-349 (1986).